These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22605964)

  • 21. Classification of acetylcholinesterase inhibitors and decoys by a support vector machine.
    Wang K; Hu X; Wang Z; Yan A
    Comb Chem High Throughput Screen; 2012 Jul; 15(6):492-502. PubMed ID: 22263859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development.
    Barreca ML; Iraci N; Manfroni G; Cecchetti V
    Future Med Chem; 2011 Jun; 3(8):1027-55. PubMed ID: 21707403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors.
    Golub AG; Gurukumar KR; Basu A; Bdzhola VG; Bilokin Y; Yarmoluk SM; Lee JC; Talele TT; Nichols DB; Kaushik-Basu N
    Eur J Med Chem; 2012 Dec; 58():258-64. PubMed ID: 23127989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
    Yu H; Fang Y; Lu X; Liu Y; Zhang H
    Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.
    Jiao P; Xue W; Shen Y; Jin N; Liu H
    Mol Biosyst; 2014 Apr; 10(4):767-77. PubMed ID: 24452008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel natural flavonoids as potent antiviral candidates against hepatitis C virus NS5B polymerase.
    Akher FB; Farrokhzadeh A; Ramharack P; Shunmugam L; Van Heerden FR; Soliman MES
    Med Hypotheses; 2019 Nov; 132():109359. PubMed ID: 31466018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study.
    Elfiky AA
    Med Chem; 2019; 15(2):130-137. PubMed ID: 30324891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Classification of active and weakly active ST inhibitors of HIV-1 integrase using a support vector machine.
    Yan A; Xuan S; Hu X
    Comb Chem High Throughput Screen; 2012 Dec; 15(10):792-805. PubMed ID: 22934952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. StackHCV: a web-based integrative machine-learning framework for large-scale identification of hepatitis C virus NS5B inhibitors.
    Malik AA; Chotpatiwetchkul W; Phanus-Umporn C; Nantasenamat C; Charoenkwan P; Shoombuatong W
    J Comput Aided Mol Des; 2021 Oct; 35(10):1037-1053. PubMed ID: 34622387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel HCV polymerase inhibitors using pharmacophore-based virtual screening.
    Kim ND; Chun H; Park SJ; Yang JW; Kim JW; Ahn SK
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3329-34. PubMed ID: 21531135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
    Elhefnawi M; ElGamacy M; Fares M
    BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.
    Court JJ; Poisson C; Ardzinski A; Bilimoria D; Chan L; Chandupatla K; Chauret N; Collier PN; Das SK; Denis F; Dorsch W; Iyer G; Lauffer D; L'Heureux L; Li P; Luisi BS; Mani N; Nanthakumar S; Nicolas O; Rao BG; Ronkin S; Selliah S; Shawgo RS; Tang Q; Waal ND; Yannopoulos CG; Green J
    J Med Chem; 2016 Jul; 59(13):6293-302. PubMed ID: 27366941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections.
    Beaulieu PL; Tsantrizos YS
    Curr Opin Investig Drugs; 2004 Aug; 5(8):838-50. PubMed ID: 15600240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
    Le Pogam S; Seshaadri A; Kosaka A; Chiu S; Kang H; Hu S; Rajyaguru S; Symons J; Cammack N; Nájera I
    J Antimicrob Chemother; 2008 Jun; 61(6):1205-16. PubMed ID: 18343801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients.
    Plaza Z; Soriano V; Gonzalez Mdel M; Di Lello FA; Macias J; Labarga P; Pineda JA; Poveda E
    J Antimicrob Chemother; 2011 Dec; 66(12):2838-42. PubMed ID: 21954459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
    Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
    J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SVM prediction of ligand-binding sites in bacterial lipoproteins employing shape and physio-chemical descriptors.
    Kadam K; Prabhakar P; Jayaraman VK
    Protein Pept Lett; 2012 Nov; 19(11):1155-62. PubMed ID: 22587788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Classification of Aurora B kinase inhibitors using computational models.
    Liu R; Nie X; Zhong M; Hou X; Xuan S; Yan A
    Comb Chem High Throughput Screen; 2014 Feb; 17(2):114-23. PubMed ID: 24152178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring hepatitis C virus (HCV) RNA-dependent RNA polymerase oligomerization by a FRET-based in vitro system.
    Bellón-Echeverría I; López-Jiménez AJ; Clemente-Casares P; Mas A
    Antiviral Res; 2010 Jul; 87(1):57-66. PubMed ID: 20430057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.